Recombinant Human Pulmonary surfactant-associated protein D (SFTPD)

^{In
Stock}

文獻(xiàn)引用 (1)

中文名稱：

人SFTPD重組蛋白
品名簡稱：

Recombinant Human SFTPD protein
貨號：

CSB-YP021175HU
說明書：

MSDS Datasheet
規(guī)格：

￥1836
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Based on the SEQUEST from database of Yeast host and target protein, the LC-MS/MS Analysis result of CSB-YP021175HU could indicate that this peptide derived from Yeast-expressed Homo sapiens (Human) SFTPD.

Based on the SEQUEST from database of Yeast host and target protein, the LC-MS/MS Analysis result of CSB-YP021175HU could indicate that this peptide derived from Yeast-expressed Homo sapiens (Human) SFTPD.
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
引用文獻(xiàn)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

SFTPD
Uniprot No.：

P35247
別名：

COLEC 7; COLEC7; Collectin-7; Collectin7; Lung surfactant protein D; PSP D; PSP-D; PSP-D Surfactant protein D; PSPD; Pulmonary surfactant apoprotein; Pulmonary surfactant associated protein D; Pulmonary surfactant associated protein PSP-D; Pulmonary surfactant-associated protein D; SFTP 4; SFTP4; SFTPD; SFTPD_HUMAN; SP D; SP-D; Surfactant associated protein pulmonary 4; Surfactant protein D; Surfactant pulmonary associated protein D
種屬：

Homo sapiens (Human)
蛋白長度：

Full Length of Mature Protein
來源：

Yeast
分子量：

35.2kDa
表達(dá)區(qū)域：

21–375aa
氨基酸序列

AEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDGREGPRGEKGDPGLPGAAGQAGMPGQAGPVGPKGDNGSVGEPGPKGDTGPSGPPGPPGVPGPAGREGPLGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGARGLAGPKGERGVPGERGVPGNTGAAGSAGAMGPQGSPGARGPPGLKGDKGIPGDKGAKGESGLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLVYSNWAPGEPNDDGGSEDCVEIF
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

N-terminal 6xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

引用文獻(xiàn)

Surfactant protein D alleviates chondrocytes senescence by upregulating SIRT3/SOD2 pathway in osteoarthritis H Jiang, Y Zhang, P Ji, J Ming, Y Li,Molecular Medicine,2025

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Contributes to the lung's defense against inhaled microorganisms, organic antigens and toxins. Interacts with compounds such as bacterial lipopolysaccharides, oligosaccharides and fatty acids and modulates leukocyte action in immune response. May participate in the extracellular reorganization or turnover of pulmonary surfactant. Binds strongly maltose residues and to a lesser extent other alpha-glucosyl moieties.
基因功能參考文獻(xiàn)：
1. these findings indicate that the membrane-type surfactant protein D serve as an effective therapeutic strategy for inhibiting macrophage-mediated xenograft rejection in xenotransplantation PMID: 29425774
2. Assays that can separate SP-D proteolytic breakdown products or modified forms from naturally occurring SP-D trimers may result in optimal disease markers for pulmonary inflammatory diseases PMID: 28960651
3. the SPA and SPD levels in EBC were correlated with lung function, which contributed to COPD diagnosis. PMID: 28791362
4. Studied predictive value of surfactant protein D (SP-D) in lung cancer patients with interstitial lung disease induced by anticancer agents (ILD-AA). Results suggest that SP-D level change was a risk factor for mortality in patients with ILD-AA, and that SP-D might be a predictive prognostic biomarker of ILD-AA. PMID: 28464801
5. SP-D also delays FasL-induced death of primary human T cells. SP-D delaying the progression of the extrinsic pathway of apoptosis could have important implications in regulating immune cell homeostasis at mucosal surfaces PMID: 28168327
6. Trimeric SP-D wildtype recognized larger LPS inner core oligosaccharides with slightly enhanced affinity than smaller compounds suggesting the involvement of stabilizing secondary interactions. PMID: 27350640
7. rs2819096 in the surfactant protein D (SFTPD) gene was associated with a higher risk of COPD GOLD III + IV. PMID: 27078193
8. SP-D increases the formation of nuclear and membrane blebs. Inhibition of caspase-8 confirms the effect of SP-D is unique to the caspase-8 pathway. PMID: 29107869
9. Findings indicate serum pulmonary surfactant protein D (SP-D, SFTPD) level as a potential marker to estimate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs). PMID: 28745320
10. Patients with SP-D 11Thr/Thr genotype were more susceptible to acute kidney injury (AKI). Compared with healthy controls, serum SP-D levels at day 1, 3 and 7 were significantly elevated in AKI patients. PMID: 28212617
11. This review intends to provide a current overview of the genetics, structure and extra-pulmonary functions of the surfactant collectin proteins. PMID: 28351530
12. Meta-analysis found that serum SP-A/D detection might be useful for differential diagnosis and prediction of survival in patients with idiopathic pulmonary fibrosis. PMID: 28591049
13. The findings suggest that SP-D inhibits LPS-stimulated production of interleukin-12p40 via the SIRPalpha/ROCK/ERK signaling pathway. PMID: 28641719
14. Efficient lipopolysaccharide recognition by SP-D requires multiple binding interactions utilizing the three major ligand-binding determinants in the SP-D binding pocket, with Ca-dependent binding of inner-core heptose accompanied by interaction of anhydro-Kdo (4,7-anhydro-3-deoxy-d-manno-oct-2-ulosonic acid) with Arg343 and Asp325. PMID: 26953329
15. SP-D levels in bronchoalveolar lavage samples were significantly lower in severe asthma compared with healthy controls and mild asthma. Serum SP-D was significantly increased in severe asthma compared with healthy controls and mild asthma. PMID: 26836907
16. Surfactant protein D levels differed among idiopathic pulmonary fibrosis, pulmonary sarcoidosis and chronic pulmonary obstructive disease. PMID: 27758987
17. Elevated levels of SP-D are Associated with Idiopathic Pulmonary Fibrosis. PMID: 27293304
18. Data do not support that pSP-D levels influence or reflect the development of subclinical atherosclerosis. However, the data support that SP-D plays a role in the etiology of atherosclerotic disease development. PMID: 26748346
19. Human and murine data together indicate that SP-A, SP-D and MBL are synthesized in early gestational tissues, and may contribute to regulation of immune response at the feto-maternal interface during pregnancy. PMID: 26603976
20. Serum SP-D may serve as a convenient medium to distinguish lung infection caused by M. pneumoniae. PMID: 26617840
21. findings shed new light on the discovery and/or development of a useful biomarker based on glycosylation changes for diagnosing COPD. PMID: 26206179
22. Quantitative real-time PCR experiments disclosed significantly increased leukocyte NOS2 and SFTPD mRNA levels in hyperglycemic gestational diabetes mellitus patients (P < 0.05). PMID: 26568332
23. Serum SP-D was not significantly different between patients with connective tissue disease-interstitial lung disease, chronic fibrosing interstitial pneumonia patients and healthy controls. PMID: 26424433
24. Letter: report higher serum SP-D levels in bird-related hypersensitivity pneumonitis during winter. PMID: 25591150
25. The SP-D level showed positive correlations with carotid IMT and coronary artery calcification in patients on long-term hemodialysis. PMID: 27012038
26. SP-D is expressed differently in airways of asthmatics relative to that of non-asthmatics. PMID: 25848896
27. Sputum and bronchoalveolar lavage fluid SFTPD were significantly higher in patients with severe asthma compared to mild-moderate asthma and healthy controls. PMID: 25728058
28. We demonstrated for the first time in a Chinese population cohort that genetic polymorphisms of SP-D are not only associated with risk of COPD development, but also related to disease manifestation and that they predict outcomes. PMID: 25376584
29. In chromium-exposed workers, blood levels of CC16, and CC16/SP-D were lower than in controls. Positive relationships were shown between CC16 or CC16/SP-D and indicators of lung function. PMID: 25851191
30. In Sjogren's syndrome, high SP-D levels were found in patients with severe glandular involvement, hypergammaglobulinemia, leukopenia, extraglandular manifestations, and positive anti-Ro/La antibodies. PMID: 25362659
31. Results revealed that higher circulating levels of SP-D are associated with higher mortality risk in critically ill A/H1N1 patients. PMID: 25537934
32. In idiopathic pleuroparenchymal fibroelastosis SP-D was elevated, while KL-6 was within a normal range. PMID: 24880792
33. These data suggest that SP-D reduces EGF binding to EGFR through the interaction between the carbohydrate recognition domain of SP-D and N-glycans of EGFR, and downregulates EGF signaling. PMID: 24608429
34. the multi-faceted role of human SP-D against HIV-1 PMID: 25036364
35. SFTPD polymorphism is associated with the risk of respiratory outcomes; it may be an essential factor affecting pulmonary adaptation in premature infants PMID: 25015576
36. Results suggest that Smokers who are carriers of the SFTPD AG and AA polymorphic genotypes may be at a higher risk of developing Chronic obstructive pulmonary disease when compared with wild-type GG genotype carriers. PMID: 24504887
37. Both mRNA and protein levels of gp340 were significantly higher in patients with biofilm associated chronic rhinosinusitis (CRS) than those with CRS and no biofilm and controls. PMID: 24121782
38. In this review, we highlight the associations of eosinophilic lung diseases with SP-A and SP-D levels and functions. PMID: 24960334
39. murine expression of human polymorphic variants does not significantly influence the severity of allergic airway inflammation PMID: 24712849
40. Genetic disposition for low surfactant protein-D was not associated with rheumatoid arthritis but with erosive rheumatoid arthritis by interaction with smoking. PMID: 24264011
41. SP-D levels were significantly higher in the sub-massive pulmonary embolism group overall. PMID: 25291941
42. a novel pathway for the immunomodulatory functions of SP-D mediated via binding of its collagenous domains to LAIR-1. PMID: 24585933
43. Human surfactant protein D alters oxidative stress and HMGA1 expression to induce p53 apoptotic pathway in eosinophil leukemic cell line. PMID: 24391984
44. Surfactant protein D substitutions at the 325 and 343 positions (D325A+R343V) exhibit markedly increased antiviral activity for seasonal strains of influenza A virus. PMID: 24705721
45. SFTPD single-nucleotide polymorphisms, rs1923536 and rs721917, and haplotypes, including these single-nucleotide polymorphisms or rs2243539, were inversely associated with expiratory lung function in interaction with smoking. PMID: 24610936
46. Increases in serum KL-6 and SP-D levels during the first 4 weeks after starting therapy, but not their levels at any one time point, predict poor prognosis in patients with polymyositis/dermatomyositis. PMID: 22983659
47. serum SP-D, but not SP-A, levels were significantly higher in the German than in the Japanese cohort PMID: 24400879
48. Lower oligomeric form of surfactant protein D is associated with cystic fibrosis. PMID: 24120837
49. Lung permeability biomakers [surfactant protein D (SP-D) and Clara cell secretory protein (CC16) in plasma] and forced expiratory volumes and flow were measured in swimmers in indoor swimming pool waters treated with different disinfection methods. PMID: 23874631
50. In patients with systemic sclerosis-related interstitial lung disease, surfactant protein D was correlated with forced vital capacity. It was not a longterm prognostic indicator. PMID: 23588945
顯示更多

收起更多
亞細(xì)胞定位：

Secreted, extracellular space, extracellular matrix. Secreted, extracellular space, surface film.
蛋白家族：

SFTPD family
組織特異性：

Expressed in lung, brain, pancreas and adipose tissue (mainly mature adipocytes).
數(shù)據(jù)庫鏈接：

HGNC: 10803

OMIM: 178635

KEGG: hsa:6441

STRING: 9606.ENSP00000361366

UniGene: Hs.253495